What is ARA-290? Research and Australian supply

ARA-290 is also called cibinetide, and Peptides Collective lists a 10mg vial from A$85. ^[1][3] The identifiers below distinguish the molecule from the amount supplied in a vial. ^[1][3]

The expanded sequence is Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, with the terminal notation recorded by PubChem as H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH. ^[1] The X is a notation for the modified first residue and is counted within the stated length. ^[1]

The Peptides Collective ARA-290 10mg product page is the ordering destination for that vial. ^[3] Request the certificate using the compound, strength and batch number so you can check the report for the material supplied. ^[2]

ARA-290 research includes human neuropathy studies, an animal neuropathic-pain study and a review of sarcoidosis-associated small fibre neuropathy. ^{[4][5][6][7][8]} The model and population belong beside each finding: a human trial, an animal experiment and a review answer different questions. ^[4][7][8]

The 2013 human publication reports changes in symptoms and corneal nerve fibre density in its title. ^[5] The 2015 human publication reports changes in metabolic control and neuropathic symptoms in adults with type 2 diabetes. ^[6] Neither captured study record provides the numerical effect sizes needed for a quantitative comparison. ^[5][6]

The animal publication links neuropathic-pain findings with the spinal microglia response, but its animal model must remain attached to that finding. ^[7] The review is a synthesis about sarcoidosis-associated small fibre neuropathy, with no additional human trial of its own. ^[8] No separately identified cell study is included in this captured evidence set. ^{[4][5][6][7][8]}

Peptides Collective groups ARA-290 within its collection of peptides studied for recovery. ^[3] The catalogue category identifies a research area; the study table supplies the specific models and populations behind the compound's literature. ^{[4][5][6][7][8][3]}

The available ARA-290 abstract excerpts do not list specific adverse-event types or rates for the sarcoidosis and type 2 diabetes trials. ^[4][6] The reporting is therefore too limited to produce an event-frequency table. ^[4][6]

Missing event detail does not establish that no adverse events occurred. ^[4][6] The available evidence comes from small trials and abstract excerpts that provide no specific event types or rates. ^[4][6] A fuller appraisal would require the papers' complete event reporting, which is not available in these excerpts. ^[4][6]

The certificate you request from Peptides Collective addresses analytical testing of a batch: purity by HPLC and identity by mass spectrometry. ^[2] Those tests answer a material-quality question, separate from the clinical event-reporting question. ^[2][4][6]

ARA-290 is not named in the June 2026 Poisons Standard, but that finding is narrower than a general legal clearance. ^[9] Our compound check, verified on 29 September 2026, records: “Not named in the Poisons Standard (June 2026 instrument); no individual entry found”. ^[9]

The source is the June 2026 instrument, F2026L00633. ^[9] The verified record supplies no individual schedule entry for ARA-290 and does not separately confirm an Appendix D entry. ^[9] Keep the named-entry finding distinct from a complete legal determination; for scheduling background, read our guide to Australian peptide law.

WADA status needs a separate reading. The checked 2026 List finding is: “Not named on the 2026 List. S2.1.5 'Innate repair receptor agonists' (e.g. asialo EPO, carbamylated EPO) is a non-exhaustive class and cibinetide is described in literature as an innate repair receptor ligand; applicability not confirmed - check with Sport Integrity Australia.” ^[10]

An absence of the individual name is not a confirmed exemption from that class. ^[10] Keep the WADA class question separate from the Australian named-entry finding. ^[9][10]

ARA-290 laboratory handling starts with checking the batch and mass basis, then recording the solvent, concentration and storage conditions. ^[11] Our house guidance separates three tasks: inspect the material and certificate, reconstitute to a known concentration, and label and store the solution. ^[11] These are general peptide-handling steps. ARA-290 has no specific stability validation in our records. ^[11][12]

1. Check the compound and batch against the certificate, including what mass basis the label and report use. ^[11] Peptides Collective makes the batch certificate available on request. ^[2]
2. Calculate concentration as peptide mass in milligrams divided by solvent volume in millilitres. ^[11] For a laboratory calculation, 10mg in 2 mL gives 5 mg/mL, using the stated peptide mass as the numerator. ^[11]
3. Record compound, batch, solvent, concentration and date, then follow the storage conditions for the material and solvent. ^[11][12]

Our peptide reconstitution guide explains the concentration calculation and gentle handling steps. ^[11] It also distinguishes label mass from net peptide content, which can affect the concentration recorded for a solution. ^[11]

The house peptide storage guide recommends keeping sealed lyophilised material dry and dark at -20°C or colder for long-term storage, and reconstituted working solutions at 2 to 8°C. ^[12] It advises avoiding repeated freezing and thawing, and keeping BAC Water solutions refrigerated. ^[12]

No ARA-290-specific stability study or validated shelf life is supplied in this evidence set. ^[11][12] The storage guide flags ARA-290's asparagine and glutamine residues, but a sequence observation cannot establish an expiry date. ^[1][12] Use the guides as general laboratory handling guidance and retain product-specific storage information with the batch record. ^[11][12]

Peptides Collective supplies ARA-290 with independent batch testing and a certificate on request, followed by tracked dispatch from Perth. ^[2][3] You can check purity and identity against a batch report because every batch is tested by an independent third-party analytical laboratory before sale. ^[2]

We arrange independent laboratory testing of purity by HPLC and identity by mass spectrometry. ^[2] Read our testing page for the process details. Request the report using the compound name, strength and batch number. ^[2] For certificate information, visit our certificate of analysis page.

Our Australian shipping information sets out the delivery terms. ^[2] The twice-daily weekday dispatch schedule gives researchers a concrete calendar to plan around, while the free-courier threshold applies specifically to WA orders over A$150. ^[2]

Choose Peptides Collective ARA-290 10mg for independent batch testing, a certificate on request and tracked Perth dispatch. ^[2][3] HPLC purity testing and mass spectrometry identity testing give you analytical information to check before laboratory work. ^[2] Dispatch is twice daily Monday to Friday and once on Saturday, with WA courier free on orders over A$150. ^[2]